Our study demonstrated that denervation of OSCC inhibited tumor growth and improved anti-PD-1 immunotherapy through downregulating TGFβ signaling and PD-L1 expression and activating CD8+ T-cell activities within the tumor microenvironment. The gene discussed is TGFB1; the disease is neoplasm.